Sensei Biotherapeutics Inc - Asset Resilience Ratio
Sensei Biotherapeutics Inc (SNSE) has an Asset Resilience Ratio of 52.48% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SNSE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Sensei Biotherapeutics Inc's Asset Resilience Ratio has changed over time. See Sensei Biotherapeutics Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sensei Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sensei Biotherapeutics Inc (SNSE) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.48 Million | 52.48% |
| Total Liquid Assets | $14.48 Million | 52.48% |
Asset Resilience Insights
- Very High Liquidity: Sensei Biotherapeutics Inc maintains exceptional liquid asset reserves at 52.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sensei Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Sensei Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Sensei Biotherapeutics Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Sensei Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 69.09% | $31.34 Million | $45.36 Million | -1.83pp |
| 2023-12-31 | 70.92% | $52.75 Million | $74.37 Million | -4.54pp |
| 2022-12-31 | 75.46% | $89.32 Million | $118.38 Million | -16.21pp |
| 2021-12-31 | 91.67% | $140.46 Million | $153.22 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $21.43 Million | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also off… Read more